Joint mechanisms of impaired growth-hormone pulse renewal in aging men

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

The objective of this study is to assess whether age attenuates and IGF-I potentiates negative feedback by a near-physiological pulse of GH.

Why It Was Studied

Experimental data indicate that high-amplitude GH pulses are evoked by reversible cycles of GH-induced negative feedback.

Whether aging impairs autofeedback is unknown.

Who Took Part

The abstract describes 17 men taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, men only.

In a university setting, 17 healthy men ages 19-71 yr each underwent four randomly ordered infusion studies on separate mornings fasting.

How the Study Was Run

In design terms this was a randomized and double-blind study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the men and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Intravenous injection of a pulse of: 1) saline or 2) recombinant human (rh) GH to impose controlled negative feedback, followed in 2 h by a bolus of 3) saline or (iv) the ghrelin analog GHRP-2 to overcome feedback inhibition.

What Was Measured

The subject headings attached to it are Aging, Feedback, Human Growth Hormone, Insulin-Like Growth Factor I and Oligopeptides.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 17 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.